The Expression of LDL-R in CD8+ T Cells Serves as an Early Assessment Parameter for the Production of TCR-T Cells

In Vivo. 2023 Nov-Dec;37(6):2480-2489. doi: 10.21873/invivo.13355.

Abstract

Background/aim: The quantity and the phenotypes of desired T cell receptor engineered T (TCR-T) cells in the final cell product determine their in vivo anti-tumor efficacy. Optimization of key steps in the TCR-T cell production process, such as T cell activation, has been shown to improve cell quality.

Materials and methods: Using a modified TCR (mTCR) derived from mice transducing PBMCs, we assessed the proportions of low-density lipoprotein receptor (LDL-R) and mTCR expressing cells under the various activation conditions of CD3/CD28-Dynabeads or OKT3 via flow cytometry.

Results: We demonstrate that the proportion of T cells expressing LDL-R post activation is positively correlated with the percentage of mTCR+CD8+ T cells with their less differentiated subtypes in the final product. In addition, we show that shifting the CD3/CD28-Dynabeads activation duration from a typical 48 h to 24 h can significantly increase the production of the desired mTCR+CD8+ T cells. Importantly, the percentages of TCR-T cells with less-differentiated phenotypes, namely mTCR central memory T cells (TCM), were found to be preserved with markedly higher efficiency when T cell activation was optimized.

Conclusion: Our findings suggest that the proportion of LDL-R+ T cells may serve as an early assessment parameter for evaluating TCR-T cell quality, possibly facilitating the functional and economical improvement of current adoptive therapy.

Keywords: CD3/CD28-Dynabeads; LDL-R; T cell phenotype; TCR-T; parameter.

MeSH terms

  • Animals
  • CD28 Antigens / metabolism
  • CD3 Complex
  • CD8-Positive T-Lymphocytes*
  • Lymphocyte Activation
  • Mice
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell / genetics

Substances

  • CD3 Complex
  • CD28 Antigens
  • Receptors, Antigen, T-Cell